Sugemalimab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | PD-L1, (CD274) |
| Clinical data | |
| Trade names | Cejemly, Eqjubi |
| Other names | CS-1001, WBP-315 |
| Routes of administration | Intravenous |
| Drug class | Antineoplastic |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
Sugemalimab, sold under the brand name Cejemly among others, is a monoclonal antibody used for the treatment of metastatic non-small cell lung cancer (NSCLC) in combination with chemotherapy. It is an antineoplastic monoclonal antibody that potentiates T-cell responses, including anti-tumor responses, through blockade of PD-1 binding to PD-L1 ligands.
The most common side effects include anemia (low red blood cells), increased levels of aminotransferases (liver enzymes), rash, hyperlipidemia (high blood fat levels), hyperglycemia (high blood glucose levels), hyponatremia (low blood levels of sodium), hypokalemia (low blood levels of potassium), proteinuria (protein in urine), abdominal (belly) pain, tiredness, arthralgia (joint pain), hypoesthesia (reduced sensation to touch, pain and temperature), hypothyroidism (underactive thyroid gland) and hypocalcemia (low blood levels of calcium).
Sugemalimab was approved for medical use in China in December 2021, the European Union in July 2024, and the United Kingdom in October 2024.